UBS Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $55
UBS analyst Michael Yee initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $55.
A big investment bank started watching Korsana and thinks it's a good company to own right now. When smart money watchers start paying attention to a company, it can mean they see something promising worth learning about.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.